CISH and neoplasm: Deletion of CISH using CRISPR/Cas9 technology has been shown to enhance TIL sensitivity to tumor neoantigens, boost cytokine secretion (e.g., IFN-γ), and improve responses to PD-1 blockade in preclinical models, laying the groundwork for combinatorial strategies that target both surface and intracellular checkpoints (166).